We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Sep 2021
  • Code : CMI4657
  • Pages : 321
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

The inner surface of the eyelid is lined with conjunctiva, a translucent tissue layer. When infected, this tissue tends to cover the white area of the eye and turn red or pink. As a result, the eye ailment conjunctivitis is often known as pink eye. The infection of the eye known as conjunctivitis is a common symptom of this ophthalmic condition. Infectious causes includes bacterial and viral infections, while non-infectious causes include allergy and immune-mediated illness inflammation. It is categorised into acute conjunctivitis, super acute conjunctivitis, and chronic conjunctivitis.

Vernal keratoconjunctivitis (VKC) is a chronic, multifactorial Th2-cell-mediated inflammatory disease of the ocular surface. It is distinguished by a large papilla on the upper tarsal conjunctiva and a corneoscleral junction. Hyperemia and mucus discharge are typical symptoms of VKC. There is no set standard treatment strategy for VKC. Mast cell stabilisers, antihistamines, nonsteroidal anti-inflammatory medications (NSAIDs), topical corticosteroids, and cyclosporine are available as treatments. Individuals receiving treatment should be continuously observed for the development of any ocular problems.

Market Dynamics

Increasing R&D activities in vernal keratoconjunctivitis for a better understanding of the disease is expected to drive the growth of global vernal keratoconjunctivitis market during the forecast period. In addition, increasing prevalence of vernal keratoconjuctivitis and supportive therapies have built the interest in several pharmaceutical companies in developing a cure for the disease. A greater knowledge of the disease's biology and manifestation of the disease has boosted efforts to develop improved treatment alternatives in the form of pipeline treatments, which is projected to propel the global vernal keratoconjunctivitis market share during the forecast period.

Key features of the study:

  • This report provides an in-depth analysis of the global vernal keratoconjunctivitis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global vernal keratoconjunctivitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
  • Key companies covered as a part of this study include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global vernal keratoconjunctivitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global vernal keratoconjunctivitis market

Detailed Segmentation:

  • Global Vernal Keratoconjunctivitis Market, By Drug Type :
    • Bertilimumab
    • Verkazia
    • Lodoxamide
    • Tacrolimus
    • Antolimab 
    • Nomacopan
    • Others
  • Global Vernal Keratoconjunctivitis Market, By Treatment:
    • Mast Cell Stabilizers
    • Antihistamines
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Topical Corticosteroids
    • Cyclosporine
    • Tacrolimus
    • Others
  • Global Vernal Keratoconjunctivitis Market, By Dosage Form:
    • Gel
    • Ointment
    • Tablet
    • Others
  • Global Vernal Keratoconjunctivitis Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Vernal Keratoconjunctivitis Market, By Region:
    • North America
      • By Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By  Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By  Drug Type
        • Bertilimumab
        • Verkazia
        • Lodoxamide
        • Tacrolimus
        • Antolimab 
        • Nomacopan
        • Others
      • By Treatment
        • Mast Cell Stabilizers
        • Antihistamines
        • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • Topical Corticosteroids
        • Cyclosporine
        • Tacrolimus
        • Others
      • By Dosage Form
        • Gel
        • Ointment
        • Tablet
        • Others
      • By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Santen *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis Pharmaceuticals
    • Senju Pharmaceutical
    • Allakos
    • iCo Therapeutics
    • Akari Therapeutics

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Treatment
      • Market Snapshot, By Dosage Form
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Developments
    • Epidemiology
    • PEST Analysis
    • Brand Analysis
  4. Global Vernal Keratoconjunctivitis Market– Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Epidemiology
    • Supply and Demand Analysis
    • Key Developments
  5. Global Vernal Keratoconjunctivitis Market, By Drug Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Bertilimumab
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Verkazia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Lodoxamide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Tacrolimus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Antolimab 
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Nomacopan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global  Vernal Keratoconjunctivitis Market, By Treatment, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Mast Cell Stabilizers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Antihistamines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Topical Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Cyclosporine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Tacrolimus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Vernal Keratoconjunctivitis Market, By Dosage Form, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Gel
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Ointment
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Tablet
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  8. Global Vernal Keratoconjunctivitis Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 – 2028
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    • Online Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
  9. Global Vernal Keratoconjunctivitis Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2028
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type , 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries/Region, 2017 – 2028, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  10. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Santen
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Novartis Pharmaceuticals
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Senju Pharmaceutical
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Allakos
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • iCo Therapeutics
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Akari Therapeutics
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
    • Analyst Views
  11. Section
    • Research Methodology
    • About us

*Browse 30 market data tables and 36 figures on "Global Vernal Keratoconjunctivitis Market” - Global forecast to 2028

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

Esomar
Duns
Clutch
DMCA

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo